Home › Enlarged Prostate (BPH) › NCT05543200
BPH Global Registry
A Global Registry of Treatments and Outcomes for Benign Prostatic Hyperplasia
Who can join
Ages 18 and older · Men
Full eligibility criteria
Inclusion Criteria: * Primary diagnosis of BPH with LUTS with prescribed medical treatment or surgical intervention Exclusion Criteria: * Non-symptomatic BPH * No treatment prescribed for BPH
About the study
Benign prostatic hyperplasia (BPH) is one of the most common performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been standardized. While data are available for the initial pivotal studies, post-market release data are lacking. Under the umbrella of uCARE, we have started a prospective, ongoing international registry for recording demographics and outcomes for patients undergoing surgical treatments for BPH.
Sponsor: Société Internationale d'Urologie · Participants: 7,500 · Started: Mar 13, 2023
Contact the study team
- Mihir Desai, MD · Phone: +1 (323) 865 3700
- Eduardo Gutierrez, PhD · Phone: +1 514 875-5665
Official record on ClinicalTrials.gov — NCT05543200
Locations in the U.S.
| California | Keck Medicine of USC, Los Angeles |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.